Corvus Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Corvus Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CRVS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001626971
- EIN
- 46-4670809
Board of directors
-
Andrew C. Chan · DirectorSince 2026
-
David Scott Moore · DirectorSince 2025
-
Den Broek Richard Van · DirectorSince 2025
-
Edith P. Mitchell · DirectorSince 2023
- Since 2023
-
Linda Grais · DirectorSince 2023
-
Peter A. Thompson · DirectorSince 2023
-
Richard A. Miller M.D. · Director · President and CEOSince 2023
- Since 2023
-
Terry P. Gould · DirectorSince 2023
Chief executives
Richard A. Miller M.D.
· President and CEO
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.2%
-
95.6%
Board connections
6 of this board's directors also sit on 18 other boards.
- via Peter A. Thompson
- via Ian T. Clark
- via Richard A. Miller M.D.
- via Peter A. Thompson
- via Ian T. Clark
- via Ian T. Clark
- via Linda Grais
- via Scott W. Morrison
- via Ian T. Clark
- via Ian T. Clark
- via Linda Grais
- via Den Broek Richard Van
- via Peter A. Thompson
- via Ian T. Clark
- via Scott W. Morrison
- via Ian T. Clark
- via Scott W. Morrison
- via Scott W. Morrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $333,654
- 3 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | David Scott Moore Director | Open-market purchase | +21,700 | $11.53 | $250,201 |
| May 18, 2026 | Richard A. Miller M.D. Director, Officer (President and CEO) | Open-market purchase | +5,000 | $12.05 | $60,250 |
| May 18, 2026 | Richard A. Miller M.D. Director, Officer (President and CEO) | Open-market purchase | +1,932 | $12.01 | $23,203 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +30,000 | $15.00 | $450,000 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $9.70 | $145,500 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $12.50 | $187,500 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $3.61 | $54,150 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $2.00 | $30,000 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $3.27 | $49,050 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $2.74 | $41,100 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $2.60 | $39,000 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $0.99 | $14,850 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $0.97 | $14,550 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $2.49 | $37,350 |
| Jan 28, 2026 | Peter A. Thompson Director, 10% owner | Option exercise | +15,000 | $1.64 | $24,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.